A multicenter randomized clinical trial evaluating interleukin-2 activated hematopoietic stem cell transplantation and post-transplant IL-2 for high risk breast cancer patients

Breast Cancer Research and Treatment

Volumn 93, Issue 2, 2005, Pages 125-134

  Isaacs, Claudine ^a   Slack, Rebecca ^a   Gehan, Edmund ^a   Ballen, Karen ^b   Boccia, Ralph ^c   Areman, Ellen ^a   Kramer, Ruthie ^a   Hayes, Daniel F ^a,d   Herscowitz, Herbert ^e   Lippman, Marc ^a,d  

^a GEORGETOWN UNIVERSITY   (United States)

^b UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

^c HOLY CROSS HOSPITAL   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^e GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Breast cancer; Immunotherapy; Interleukin 2; Stem cell transplantation

Indexed keywords

ANTIEMETIC AGENT; ANTINEOPLASTIC AGENT; CARBOPLATIN; CYCLOPHOSPHAMIDE; DIPHENHYDRAMINE; IMMUNOMODULATING AGENT; INTERLEUKIN 2; LORAZEPAM; MESNA; ONDANSETRON; THIOTEPA;

ACUTE GRAFT VERSUS HOST DISEASE; ADOLESCENT; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; AXILLARY LYMPH NODE; BLOOD CLOTTING DISORDER; BREAST CANCER; CANCER IMMUNOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ESOPHAGITIS; EVALUATION; FEMALE; FLU LIKE SYNDROME; FOLLOW UP; GASTROINTESTINAL SYMPTOM; HEMORRHAGIC CYSTITIS; HIGH RISK PATIENT; HUMAN; HYDRATION; INCUBATION TIME; INFECTION; LOW DRUG DOSE; LUNG DISEASE; MAJOR CLINICAL STUDY; METABOLIC DISORDER; MULTICENTER STUDY; NEUTROPHIL; PHASE 3 CLINICAL TRIAL; PHLEBITIS; POSTOPERATIVE CARE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SKIN MANIFESTATION; STATISTICAL ANALYSIS; STOMATITIS; SURVIVAL RATE; SURVIVAL TIME; THROMBOCYTE; THROMBOPHLEBITIS;

ADOLESCENT; ADULT; AGED; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GRAFT VS HOST DISEASE; HUMANS; INTERLEUKIN-2; MIDDLE AGED; NEOPLASM STAGING; STEM CELL TRANSPLANTATION; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 25844474411     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-005-4445-y     Document Type: Article

References (43)

1. EA Stadtmauer A O'Neill LJ Goldstein PA Crilley KF Mangan JN Ingle I Brodsky S Martino HM Lazarus JK Erban C Sickles JH Glick 2000 Conventional-dose chemotherapy compared with high-dose chemotherapy plus autologous hematopoietic stem-cell transplantation for metastatic breast cancer. Philadelphia bone marrow transplant group N Engl J Med 342 1069 1076
2. S Rodenhuis M Bontenbal LVAM Beex J Wagstaff DJ Richel MA Nooij EE Voest P Hupperets H van Tinteren HL Peterse EM TenVergert EGE de Vries 2003 The Netherlands working party on Autologous Transplantation in Solid Tumors: High-dose chemotherapy with hematopoietic stem-cell rescue for high risk breast cancer Engl J Med 349 7 16
3. H Roche P Viens P Biron JP Lotz B Asselain 2003 High-dose chemotherapy for breast cancer: the French PEGASE experience Cancer Control 10 42 47
4. MS Tallman R Gray NJ Robert CF LeMaistre CK Osborne WP Vaughan WJ Gradishar TM Pisansky J Fetting E Paietta HM Lazarus 2003 Conventional adjuvant chemotherapy with or without high-dose chemotherapy and autologous stem-cell transplantation in high-risk breast cancer N Engl J Med 349 17 26
5. AR Zander N Kroger C Schmoor W Kruger V Mobus N Frickhofen B Metzner W Schultze WE Berdel M Koenigsmann E Thiel H Wandt K Possinger L Trumper R Kreienberg M Carstensen EH Schmidt F Janicke M Schumacher W Jonat 2004 High-dose chemotherapy with autologous hematopoietic stem-cell support compared with standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: first results of a randomized trial J Clin Oncol 22 2273 2283
6. Antman KH: Overview of the six available randomized trials of high-dose chemotherapy with blood or marrow transplant in breast cancer. J Natl Cancer Inst Monogr:114-116, 2001
7. The Scandinavian Breast Cancer Study Group: Results from a randomized adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. Proc Am Assoc Clin Oncol 18: 2a, 1999
8. Peters WP, Rosner G, Vredenburgh J, Shpall E, Crump M, Marks L, Cirrincione C, Hurd D, Norton L: Updated results of a prospective randomized comparison of two doses of combination alkylating agents as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes: CALGB 9082/SWOG 9114/NCIC MA-13. Proc Am Assoc Clin Oncol. 20: 21a, 2001
9. WP Peters M Ross JJ Vredenburgh B Meisenberg B Marks LB Marks E Winder J Kurtzberg RC Bast Jr R Jones E Shpall K Wu G Rosner C Gilbert B Mathias D Coniglio W Petros IC Henderson L Norton RB Weiss D Budman D Hurd 1993 High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer J Clin Oncol 11 1132 1143
10. Z Rahman D Frye A Buzdar T Smith L Asmar R Champlin G Hortobagyi 1997 Impact of selection process on response rate and long-term survival of potential high-dose chemotherapy candidates treated with standard-dose doxorubicin-containing chemotherapy in patients with metastatic breast cancer J Clin Oncol 15 3171 3177
11. KR Meehan UN Verma R Cahill S Frankel EM Areman RA Sacher R Foelber C Rajagopal EA Gehan ME Lippman A Mazumder 1997 Interleukin-2-activated hematopoietic stem cell transplantation for breast cancer: investigation of dose level with clinical correlates Bone Marrow Transplant 20 643 651
12. KR Meehan UN Verma C Rajogopal R Cahill S Frankel A Mazumder 1996 Stem cell transplantation with chemoradiotherapy myeloablation and interleukin-2 J Infus Chemother 6 28 32
13. KR Meehan B Arun EA Gehan B Berberian V Sulica EM Areman A Mazumder ME Lippman 1999 Immunotherapy with interleukin-2 and alpha-interferon after IL-2-activated hematopoietic stem cell transplantation for breast cancer Bone Marrow Transplant 23 667 673
14. KH Antman PA Rowlings WP Vaughan CJ Pelz JW Fay KK Fields CO Freytes RP Gale BE Hillner HK Holland MJ Kennedy JP Klein HM Lazarus PL McCarthy Jr. R Saez G Spitzer EA Stadtmauer SF Williams S Wolff KA Sobocinski JO Armitage MM Horowitz 1997 High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America [see comments] J Clin Oncol 15 1870 1879
15. UN Verma E Areman SA Dickerson PL Kotula R Sacher A Mazumder 1995 Interleukin-2 activation of chemotherapy and growth factor-mobilized peripheral blood stem cells for generation of cytotoxic effectors Bone Marrow Transplant 15 199 206
16. TD Horn 1994 Acute cutaneous eruptions after marrow ablation: roses by other names? J Cutan Pathol 21 385 392
17. S Rodenhuis E van der Richel d Wall J Schornagel J Baars C Koning J Peterse J Borger W Nooijen R Bakx O Dalesio E Rutgers 1998 Randomised trial of high-dose chemotherapy and haemopoietic progenitor-cell support in operable breast cancer with extensive axillary lymph-node involvement Lancet 352 515 521
18. E Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 481
19. E Gehan 1965 A generalized Wilcoxon test for comparing arbitrarily singly-censored samples Biometrika 52 203 223
20. DR Cox 1972 Regression models and life tables J Roy Stat Soc B 34 187 202
21. BS Charak B Malloy R Agah A Mazumder 1990 A novel approach to purging of leukemia by activation of bone marrow with interleukin 2 Bone Marrow Transplant 6 193 198
22. MJ Kennedy 1994 Induced autologous graft-versus-host disease for the treatment of cancer Cancer Treat Rev 20 97 103
23. AM Yeager GB Vogelsang RJ Jones ER Farmer V Altomonte AD Hess GW Santos 1992 Induction of cutaneous graft-versus-host disease by administration of cyclosporine to patients undergoing autologous bone marrow transplantation for acute myeloid leukemia Blood 79 3031 3035
24. RJ Jones GB Vogelsang AD Hess ER Farmer RB Mann RB Geller S Piantadosi GW Santos 1989 Induction of graft-versus-host disease after autologous bone marrow transplantation Lancet 1 754 757
25. MJ Kennedy GB Vogelsang RA Beveridge ER Farmer V Altomonte AM Huelskamp NE Davidson 1993 Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer J Clin Oncol 11 478 484
26. R Agah B Malloy M Kerner E Girgis P Bean P Twomey A Mazumder 1989 Potent graft antitumor effect in natural killer-resistant disseminated tumors by transplantation of interleukin 2-activated syngeneic bone marrow in mice Cancer Res 49 5959 5963
27. S Giralt D Weber M Colome M Dimopoulos R Mehra K Van Besien J Gajewski B Andersson I Khouri D Przepiorka B von Wolff K Delasalle M Korbling D Seong R Alexanian R Champlin 1997 Phase I trial of cyclosporine-induced autologous graft-versus-host disease in patients with multiple myeloma undergoing high-dose chemotherapy with autologous stem-cell rescue J Clin Oncol 15 667 673
28. C Massumoto MC Benyunes G Sale M Beauchamp A York JA Thompson CD Buckner A Fefer 1996 Close simulation of acute graft-versus-host disease by interleukin-2 administered after autologous bone marrow transplantation for hematologic malignancy Bone Marrow Transplant 17 351 356
29. PL Weiden KM Sullivan N Flournoy R Storb ED Thomas 1981 Antileukemic effect of chronic graft-versus-host disease: contribution to improved survival after allogeneic marrow transplantation N Engl J Med 304 1529 1533
30. RJ Jones RF Ambinder S Piantadosi GW Santos 1991 Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation Blood 77 649 653
31. CA Keever K Pekle MV Gazzola NH Collins A Gillio 1990 NK and LAK activities from human marrow progenitors. I The effects of interleukin-1 and interleukin-2 Cell Immunol 126 211 226
32. BS Charak R Agah D Gray A Mazumder 1991 Interaction of various cytokines with interleukin 2 in the generation of killer cells from human bone marrow: application in purging of leukemia Leuk Res 15 801 810
33. BS Charak GD Choudhary M Tefft A Mazumder 1992 Interleukin-2 in bone marrow transplantation: preclinical studies Bone Marrow Transplant 10 103 111
34. BS Charak R Agah RK Brynes M Chogyoji S Groshen SC Chen A Mazumder 1992 Interleukin-2 (IL-2) and IL-2-activated bone marrow in transplantation: evaluation from a clinical perspective Bone Marrow Transplant 9 479 486
35. BS Charak RK Brynes S Groshen SC Chen A Mazumder 1990 Bone marrow transplantation with interleukin-2-activated bone marrow followed by interleukin-2 therapy for acute myeloid leukemia in mice Blood 76 2187 2190
36. UN Verma A Bagg E Brown A Mazumder 1994 Interleukin-2 activation of human bone marrow in long-term cultures: an effective strategy for purging and generation of anti-tumor cytotoxic effectors Bone Marrow Transplant 13 115 123
37. KR Meehan K Ballen R Boccia 1994 A multicenter phase I trial using STAMP V (CTCb) with IL-2 activated PBSC and IL-2 post transplantation for women with high-risk breast cancer Blood 92 abs
38. C Herrera MJ Garcia-Perez R Ramirez C Martin MA Alvarez F Martinez P Gomez JM Garcia-Castellano A Torres 1997 Lymphokine-activated killer (LAK) cell generation from peripheral blood stem cells by in vitro incubation with low-dose interleukin-2 plus granulocyte-macrophage colony-stimulating factor Bone Marrow Transplant 19 545 551
39. KR Meehan R Slack E Gehan HB Herscowitz EM Areman M Ebadi MS Cairo ME Lippman 2002 Mobilization of peripheral blood stem cells with paclitaxel and rhG-CSF in high-risk breast cancer patients J Hematother Stem Cell Res 11 415 421
40. MJ Pittet DE Speiser D Valmori JC Cerottini P Romero 2000 Cutting edge: cytolytic effector function in human circulating CD8+ T cells closely correlates with CD56 surface expression J Immunol 164 1148 52
41. B Zoll P Lefterova M Csipai S Finke B Trojaneck O Ebert B Micka K Roigk M Fehlinger GD Schmidt-Wolf D Huhn IG Schmidt-Wolf 1998 Generation of cytokine-induced killer cells using exogenous interleukin-2, -7 or -12 Cancer Immunol Immunother 47 221 226
42. GD Schmidt-Wolf RS Negrin IG Schmidt-Wolf 1997 Activated T cells and cytokine-induced CD3+CD56+ killer cells Ann Hematol 74 51 56
43. J Crown 2004 Smart bombs versus blunderbusses: high-dose chemotherapy for breast cancer Lancet 364 1299 1300